Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.35 HKD | +0.71% | -1.38% | +4.65% |
May. 15 | China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection | MT |
May. 14 | China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 0.12 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.65% | 8.46B | C | ||
-1.52% | 24.18B | C+ | ||
+8.55% | 8.34B | B | ||
-23.71% | 7.64B | B- | ||
+15.20% | 5.33B | B- | ||
+2.68% | 4.12B | B | ||
-6.90% | 3.92B | B- | ||
+5.56% | 3.89B | B+ | ||
+18.80% | 3.54B | C+ | ||
+3.11% | 3.09B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1099 Stock
- Ratings Sinopharm Group Co. Ltd.